Sunshine Biopharma Inc. (SBFM) - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) covers events occurring on April 2, 2025, with the offering closing on April 3, 2025. Sunshine Biopharma Inc., a Colorado corporation headquartered in Fort Lauderdale, Florida, announced the completion of a registered direct offering of its common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
- Securities Issued: 928,404 shares of common stock and pre-funded warrants to purchase up to 260,000 shares.
- Pricing: Common stock sold at $2.07 per share; pre-funded warrants sold at $2.06999 per warrant.
- Net Proceeds: Approximately $1.8 million after deducting estimated offering expenses and placement agent fees.
- Placement Agent Fees: Aegis Capital Corp. received a cash fee of 8% of aggregate gross proceeds plus expense reimbursement.
- Use of Proceeds: General corporate purposes, including working capital.
Note: This filing does not provide data on revenue, profit, cash flow, margins, or existing debt levels, as it reports a specific capital raising event rather than periodic financial results.
Material Changes
The primary material change is the increase in outstanding share count and the infusion of liquidity via the registered direct offering. The transaction was executed pursuant to a Registration Statement on Form S-3 (File No. 333-284142) declared effective on January 15, 2025.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to support general corporate operations and working capital needs. The filing references legal opinions regarding the legality of the issuance and enforceability of the warrants. No specific forward-looking guidance regarding product development timelines or future revenue projections is included in this specific document.
Investor Verification Checklist
- Verify the exact number of shares issued and the dilution impact on existing shareholders.
- Confirm the total gross proceeds raised before fees to assess the full capital raised.
- Review the attached Securities Purchase Agreement (Exhibit 10.1) for any specific covenants or restrictions.
- Check the press releases (Exhibits 99.1 and 99.2) for additional context on the strategic rationale.
- Monitor subsequent filings for the impact of this capital raise on the company's cash runway.